OTTAWA, May 14, 2014 /CNW/ - Health Canada has completed a safety review of the serotonin blocking drugs dolasetron (ANZEMET), granisetron (KYTRIL and generics), ondansetron (ZOFRAN and generics) and palonosetron (ALOXI), which are used for treating nausea and vomiting. This review identified a potential risk of serotonin syndrome.
Serotonin syndrome occurs when serotonin, a chemical normally found in the body, accumulates to high levels. This usually happens with combinations of certain serotonin drugs, but may also occur with a single drug.
It is very important to diagnose serotonin syndrome early as it can be fatal if not treated. Symptoms of serotonin syndrome may include agitation, confusion, fast heartbeat, muscle twitching or stiffness, fever, loss of consciousness or coma. As serotonin syndrome can be misdiagnosed, it is important that patients who experience any of these symptoms should talk to a healthcare practitioner immediately.
The Canadian Product Monographs for ALOXI, KYTRIL and ZOFRAN now contain this new safety information. ANZEMET has been withdrawn from the Canadian market by the manufacturer. Manufacturers of generic versions of these drugs will also update their Product Monographs.
Health Canada has received two domestic reports of serotonin syndrome involving this class of drugs. The reported cases did not result in fatalities. Cases of serotonin syndrome or other serious or unexpected adverse reactions in patients receiving these drugs should be reported to the manufacturers, or to Health Canada.
Serotonin Blockers Summary Safety Review
Report health or safety concerns
- Call toll-free at 1-866-234-2345
- Visit MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax
SOURCE: Health Canada
For further information:
Également disponible en français